kwd 2131 has been researched along with Bronchospasm in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hegardt, B; Löwhagen, O; Svedmyr, N | 2 |
| Hegardt, B; Pauwels, R; Van Der Straeten, M | 1 |
| Granerus, G; Hegardt, B; Löwhagen, O; Svedmyr, N | 1 |
4 trial(s) available for kwd 2131 and Bronchospasm
| Article | Year |
|---|---|
Histamine-induced bronchospasm. Its reproducibility and usage in clinical evaluation of the sub-threshold bronchodilating dose of a new beta-agonist, KWD 2131.
Topics: Adrenergic beta-Agonists; Adult; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Bronchodilator Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Histamine; Humans; Male; Middle Aged; Terbutaline | 1980 |
Evaluation of the protective effect of a new beta-agonist, KWD 2131, on allergen-induced bronchospasm.
Topics: Adrenergic beta-Agonists; Adult; Allergens; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Clinical Trials as Topic; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Placebos; Terbutaline | 1980 |
Inhibitory effect of KWD 2131, terbutaline, and DSCG on the immediate and late allergen-induced bronchoconstriction.
Topics: Adrenergic beta-Agonists; Adult; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Clinical Trials as Topic; Cromolyn Sodium; Female; Forced Expiratory Volume; Humans; Male; Random Allocation; Terbutaline | 1981 |
The protective property of equipotent bronchodilating doses of inhaled KWD 2131 and terbutaline against allergen-induced bronchospasm.
Topics: Administration, Intranasal; Adult; Allergens; Bronchial Provocation Tests; Bronchial Spasm; Bronchodilator Agents; Female; Forced Expiratory Volume; Histamine; Humans; Male; Terbutaline | 1982 |